
|Slideshows|March 26, 2015
MS and Natalizumab: 3 New Findings
Author(s)Sreeram Ramagopalan, PhD
Three brand new studies shed light on use of natalizumab in relapsing-remitting multiple sclerosis.
Advertisement
Natalizumab is a highly effective therapy for relapsing-remitting multiple sclerosis. However, its efficacy in the context of other more recently available treatments needs to be assessed. Further, hampering the long-term of use of natalizumab is the association of treatment with a risk of progressive multifocal leukoencephalopathy (PML).The slides above highlight findings of 3 new studies of natalizumab.  Â
Advertisement
Latest CME
Advertisement
Advertisement
Trending on NeurologyLive - Clinical Neurology News and Neurology Expert Insights
1
FDA Approves Apitegromab for Spinal Muscular Atrophy
2
8 Emerging Therapies Shaping the Muscular Dystrophy Treatment Landscape
3
FDA Priority Review Puts Satralizumab on Track as First MOGAD Drug
4
AAN, AHS Issue Updated Guideline on Migraine Prevention, Atogepant Meets End Points in Phase 3 Trial, Trientine Enters Phase 3 Trial
5










